Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

Benzinga Newsdesk www.benzinga.com Negative 87.5%

Neg 87.5% Neu 0% Pos 0%

Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.